title: Dispensing of fluticasone propionate/salmeterol combination in the summer and asthma-related outcomes in the fall.
abstract: BACKGROUND
  Asthma exacerbations occur year-round; however, peak asthma-related events occur in the fall and are frequently associated with viral respiratory infections.
  
  
  OBJECTIVE
  To compare the rates of asthma-related emergency department (ED) visits and hospitalizations in the fall (September, October, November) between users and nonusers of fluticasone propionate plus salmeterol in a single inhaler (FSC) in the preceding summer.
  
  
  METHODS
  This was a retrospective, observational study using health care claims from a large managed care database. Patients age 4 to 55 years with both a medical claim for asthma and a pharmacy claim for FSC were categorized into 3 age groups: children (4-11 years), adolescents (12-18 years), and adults (19-55 years).
  
  
  RESULTS
  There were 201,973 observations of FSC dispensings and 184,143 observations without FSC. Across all age groups, summertime dispensings of FSC were associated with a significantly lower (P < .001) risk of an asthma-related ED visit (4-11 years: adjusted odds ratio [OR], 0.54, 95% CI, 0.49-0.60; 12-18 years: OR, 0.59, 95% CI, 0.54-0.64; 19-55 years: OR, 0.53, 95% CI, 0.51-0.55) or hospitalization (4-11 years: OR, 0.43, 95% CI, 0.35-0.54; 12-18 years: OR, 0.49, 95% CI, 0.40-0.60; 19-55 years: OR, 0.61, 95% CI, 0.57-0.65) in the subsequent fall. This protective effect persisted even for patients with fall dispensings of FSC. The risk of oral corticosteroid dispensing in the fall was also significantly reduced in all age groups.
  
  
  CONCLUSIONS
  Summertime dispensings of FSC were associated with a decreased risk of serious asthma-related outcomes in the subsequent fall. Continuous use of FSC before seasonal viral exposure may decrease seasonally related exacerbations.
authors.affiliation: Jacqueline Neimark Laboratory ofClinical Pharmacology in Pediatrics, National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206, USA. spahnj@njc.org
authors.forename: Joseph
authors.initials: J
authors.lastname: Spahn
authors.forename: Ketan
authors.initials: K
authors.lastname: Sheth
authors.forename: Wei-Shi
authors.initials: WS
authors.lastname: Yeh
authors.forename: David A
authors.initials: DA
authors.lastname: Stempel
authors.forename: Richard H
authors.initials: RH
authors.lastname: Stanford
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use*; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D004636:Emergency Service, Hospital; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D012189:Retrospective Studies; D000068299:Salmeterol Xinafoate; D012621:Seasons; D055815:Young Adult
chemical_list: D000318:Adrenergic beta-Agonists; D000730:Androstadienes; D018926:Anti-Allergic Agents; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol